PL1802573T3 - Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny - Google Patents

Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny

Info

Publication number
PL1802573T3
PL1802573T3 PL05793645T PL05793645T PL1802573T3 PL 1802573 T3 PL1802573 T3 PL 1802573T3 PL 05793645 T PL05793645 T PL 05793645T PL 05793645 T PL05793645 T PL 05793645T PL 1802573 T3 PL1802573 T3 PL 1802573T3
Authority
PL
Poland
Prior art keywords
methanesulfonylphenyl
piperidine
propyl
synthesis
Prior art date
Application number
PL05793645T
Other languages
English (en)
Inventor
Donald R. Gauthier
Richard Desmond
Paul N. Devine
Original Assignee
Teva Pharmaceuticals International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International Gmbh filed Critical Teva Pharmaceuticals International Gmbh
Publication of PL1802573T3 publication Critical patent/PL1802573T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05793645T 2004-10-13 2005-10-13 Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny PL1802573T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61819604P 2004-10-13 2004-10-13

Publications (1)

Publication Number Publication Date
PL1802573T3 true PL1802573T3 (pl) 2017-03-31

Family

ID=35478927

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05793645T PL1802573T3 (pl) 2004-10-13 2005-10-13 Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny

Country Status (14)

Country Link
US (1) US7923459B2 (pl)
EP (1) EP1802573B1 (pl)
JP (1) JP4891908B2 (pl)
KR (1) KR101319235B1 (pl)
CN (1) CN101056854B (pl)
AU (1) AU2005293754B2 (pl)
CA (1) CA2584831C (pl)
DK (1) DK1802573T3 (pl)
ES (1) ES2659577T3 (pl)
HU (1) HUE029790T2 (pl)
MX (1) MX2007004215A (pl)
NZ (1) NZ555094A (pl)
PL (1) PL1802573T3 (pl)
WO (1) WO2006040155A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
KR101245075B1 (ko) 2004-06-08 2013-03-18 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
CA2584833A1 (en) * 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
WO2008127188A1 (en) * 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EA201691454A1 (ru) 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) * 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR105434A1 (es) * 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US20200375966A1 (en) 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
PL4005570T3 (pl) 2016-09-16 2024-09-23 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu retta
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
EP4620471A3 (en) 2017-08-14 2025-11-26 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
CA3167214A1 (en) 2020-02-13 2021-08-19 Michal Geva Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2023214412A1 (en) 2022-05-03 2023-11-09 Prilenia Neurotherapeutics Ltd. Processes and intermediates for the preparation of pridopidine
WO2026038220A1 (en) 2024-08-15 2026-02-19 Prilenia Neurotherapeutics Ltd. Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (pl) * 1964-04-14
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4048314A (en) * 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4333942A (en) * 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) * 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
EP0094159B1 (en) 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
US4504660A (en) * 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DK0641320T3 (da) * 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ES2225979T3 (es) * 1996-07-22 2005-03-16 Daiichi Suntory Pharma Co., Ltd. Derivados de arilpiperidinol y de arilpiperidina y farmacos que los contienen.
US5892041A (en) * 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
DE60025604T2 (de) 1999-06-22 2006-07-27 Neurosearch A/S Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2001280599A1 (en) 2000-07-15 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
CA2432985A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Piperazine- and piperidine-derivatives as melanocortin receptor agonists
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP2204363A1 (en) 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CA2584833A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
CN101056854A (zh) 2007-10-17
AU2005293754A1 (en) 2006-04-20
CA2584831A1 (en) 2006-04-20
ES2659577T3 (es) 2018-03-16
HUE029790T2 (hu) 2017-04-28
KR20070065911A (ko) 2007-06-25
US20070238879A1 (en) 2007-10-11
JP2008515951A (ja) 2008-05-15
MX2007004215A (es) 2007-12-12
HK1105195A1 (zh) 2008-02-06
US7923459B2 (en) 2011-04-12
CN101056854B (zh) 2013-06-05
AU2005293754B2 (en) 2011-07-21
EP1802573B1 (en) 2016-09-28
JP4891908B2 (ja) 2012-03-07
CA2584831C (en) 2013-09-17
DK1802573T3 (en) 2016-12-19
EP1802573A1 (en) 2007-07-04
WO2006040155A1 (en) 2006-04-20
NZ555094A (en) 2009-07-31
KR101319235B1 (ko) 2013-10-16

Similar Documents

Publication Publication Date Title
PL1802573T3 (pl) Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny
ZA200705130B (en) Process for the synthesis of azetidinones
PL1761510T3 (pl) Sposób wytwarzania 4-(benzimidazolilometyloamino)-benzamidyn
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
ZA200700685B (en) Novel piperidine derivative for the treatment of depression
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
IL185419A0 (en) Improved process for the synthesis of enantiomeric indanylamine derivatives
IL183528A0 (en) Process for preparing rosuvastatin
SI1807395T1 (sl) Proces za sintezo N-alkoksiaminov
GB0623764D0 (en) Process for the synthesis of hydromorphone
HUP0500537A3 (en) Process for the preparation of rosuvastatin via new intermediates
IL177039A0 (en) Improved process for preparing rebamipide
HU0402017D0 (en) Environment-friend process for the synthesis of quaternary ammonio-steroids
IL182134A0 (en) Process for production of 2-chloro-4-nitroimidazole
GB0505861D0 (en) Methods for the synthesis of heteroaromatic compounds
IL162071A0 (en) Process for synthesis of dinitrotetraoxadiazaisowurzitane (dtiw)
IL181075A0 (en) Process for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine
HU0401379D0 (en) Process for the preparation of risperidon
IL180345A0 (en) Improved process for the manufacture of mirtazapine
ZA200804778B (en) New process for the preparation of esomeprazole non-salt form
PL378094A1 (pl) Sposób wytwarzania aldehydów
EG24122A (en) Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolines
HK1105194A (en) Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
IL178960A0 (en) Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds
ZA200601986B (en) Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile